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Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) which inhibits both 
isoforms of cyclo-oxygenase: COX-1 and COX-2. Its nephrotoxicity has been 
reported to be fatal to vultures but this was not so with meloxicam, a COX-2 selective 
NSAID. The present study aimed to investigate the difference in toxicity of 
meloxicam and diclofenac using isolated kidney mitochondria and cultured MDCK II 
and LLC-PK1 renal cells, which represent renal distal and proximal tubular cells, 
respectively. Both drugs were shown to cause mitochondrial dysfunction by 
uncoupling oxidative phosphorylation resulting in a compromise in mitochondrial 
membrane potential and a decrease in the rate of ATP biosynthesis. However, ATP 
biosynthesis from the oxidation of glutamate/malate was significantly more 
compromised compared to that of succinate when the mitochondria were incubated 
with diclofenac; this phenomenon was absent under meloxicam treatment. Inhibition 
of the malate-aspartate shuttle by diclofenac with a resultant decrease in the ability of 
mitochondria to generate NAD(P)H was demonstrated. Diclofenac however had no 
effect on the activities of NADH dehydrogenase, glutamate dehydrogenase and 
malate dehydrogenase. It was therefore concluded that the decreased NAD(P)H 
production due to the inhibition of the entry of malate and glutamate via the malate-
aspartate shuttle explained the more pronounced decreased rate of ATP biosynthesis 
from glutamate/malate by diclofenac. Experiments using cultured kidney cells showed 
that both meloxicam and diclofenac decreased the viability of MDCK II and LLC-PK1 
cells. Diclofenac was more toxic than meloxicam to both cell lines. LLC-PK1 cells 
were more sensitive to both drugs compared to MDCK II cells. In an attempt to 
elucidate the mechanism of cell death induced by diclofenac and meloxicam, it was 
found that exposure of MDCK II cells to meloxicam caused the appearance of 
 vi
apoptotic bodies. This was accompanied by positive annexin V-FITC staining, 
elevation of intracellular ATP, activation of caspase-9 and caspase-3 and release of 
cytochrome c, implicating an intrinsic mitochondrial cell death pathway by apoptosis. 
Diclofenac-treated MDCK II cells on the other hand showed apoptotic features during 
early cell death but switched to necrosis after extended period of drug exposure as 
evidenced by the increased propidium iodide staining with cell remnants remained 
attached to the culture flasks. The mode of cell death in LLC-PK1 cells was however 
less well-defined with positive annexin V-FITC staining and release of cytochrome c 
into cytosol but minimal increase in caspase-3 activity with no elevation of 
intracellular ATP level, suggestive of a caspase-independent pathway. Propidium 
iodide staining revealed that a huge population of drug-treated LLC-PK1 cells was 
undergoing necrosis. In short, both diclofenac and meloxicam uncoupled oxidative 
phosphorylation but different modes of nephrotoxic cell death had been 
identified: MDCK II cells treated with meloxicam seemed to die by apoptosis, but 
diclofenac seemed to favor necrosis. A significant fraction of cell death induced by 
meloxicam and diclofenac in LLC-PK1 cells was caspase-independent and most likely 
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1.1 Overview of nonsteroidal anti-inflammatory drugs (NSAIDs) – COX-2-   
selective and nonselective NSAIDs 
Diclofenac and meloxicam belong to the family of nonsteroidal anti-inflammatory 
drugs (NSAIDs) - a heterogeneous group of compounds which are chemically 
unrelated yet they share similar pharmacologic properties as well as side effects. 
NSAIDs are frequently prescribed because of their analgesic and antipyretic 
properties and they are easily available through prescriptions by physicians as well as 
over-the-counter (OTC). The widespread use of these agents support the notion that 
NSAIDs are effective drugs in the treatment of the many clinical conditions for which 
they are prescribed. NSAIDs exert their effects mainly through the inhibition of the 
cyclooygenases (COXs), which are bifunctional hemoproteins that catalyze the 
bisoxygenation of arachidonic acid to prostaglandin H2, which serves as the common 
precursor for the synthesis of prostaglandins, prostacyclins and thromboxanes, 
collectively known as prostanoids (Chan et al., 1999). The mechanism of action of 





Fig. 1. Mechanism of action of NSAIDs. Prostanoids are derived from phospholipids 
in the cell membrane via the cyclo-oygenase and lipo-oxygenase pathways. NSAIDs 




COX exists in two isoforms: the constitutive COX-1, which is present in many 
tissues, particularly the stomach, kidneys, and platelets, and mediates routine 
homeostatic actions of prostanoids including gastric mucosal protection and normal 
platelet function. The inducible COX-2 is expressed in response to inflammatory 
stimulus, growth factors, cytokines and mitogens (Harirforoosh and Jamali, 2005). All 
NSAIDs inhibit COX-1 and -2 to varying degrees and the selectivity of an NSAID for 
the two COX isoforms may be described by the COX-2/COX-1 ratio; this ratio is 
calculated from the half maximal inhibitory concentrations (IC50) for both isoforms 
and a number of studies have been carried out to assess the selectivity of various 
NSAIDs in clinical use (Furst, 1997). Agents that selectively inhibit COX-2 have the 
theoretical advantage that they are potent inhibitors of the inflammatory response but 
have a low potential for renal and gastric adverse effects. Meloxicam has been 
developed for its selectivity towards COX-2. It has consistently shown selectivity for 
COX-2 in in vitro and ex vivo human cell assays and in in vivo assays of renal 
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function and platelet aggregation, although it still retains some activity against COX-1 
(Furst, 1997). While meloxicam has been shown to exhibit greater COX-2 selectivity, 
diclofenac was approximately equipotent against both COX isoforms (Churchill et al., 
1996).  
 
1.2 Adverse effects of nonselective and COX-2-selective NSAIDs 
NSAIDs are not free from unwanted adverse effects. In fact, they are associated 
with a wide array of alterations in gastrointestinal (GI) integrity and function (Wallace, 
1997; Somasundaram et al, 1995; Ashton and Hanson, 2002; Mahmud et al., 1996; 
Ohe et al., 1980). Among the most common are hemorrhagic gastric erosions, which 
usually heal within a few days and occur less frequently as NSAID use is continued. 
However, NSAID-induced gastric ulcers are of greater clinical significance because 
of their chronicity and significant bleeding. Moreover, NSAIDs can also induce 
damage to the more distal regions of the small intestine causing colonic ulcer, which 
is rare but often serious.  
 
While the gastrointestinal toxicity associated with NSAIDs medication is well 
known, it has become increasingly apparent that the liver and kidney are also 
important targets for untoward clinical events (Rostom et al., 2005; Boelsterli, 2003; 
Rabinovitz and Thiel, 1992; Murray and Brater, 1993; Dunn, 1984; Palmer, 1995; 
Clive and Stoff, 1984). Although the epidemiological risk of clinically apparent liver 
injury is low, but when it occurs, it can be fatal and can cause diagnostic confusion. In 
general, the clinical manifestations of NSAID toxicity in liver can present as two 
distinct forms, mild hepatic changes and the more significant hepatic injuries. The 
mild hepatic changes, which are relatively frequent and usually observed in phase III 
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clinical trial prior to marketing, are evident as minor increases in liver enzymes in the 
plasma. On the other hand, the latter form of liver injury is rare but can have fatal 
outcome. NSAID-induced hepatotoxicity occurs only in a minority population of 
patients and is often not recognized as a possible adverse event until the post 
marketing stage. In general, the mechanism is thought to be an idiosyncratic reaction 
(immunologic or metabolic) rather than an intrinsic toxicity of the agent. Although 
hepatotoxicity has been attributed to the entire therapeutic class of NSAIDs, the rates 
and types of injury often vary within and between chemical classes. 
 
NSAIDs can affect renal function in a variety of ways by inhibiting synthesis of 
renal prostaglandins that are important for solute homeostasis and for maintaining 
renal blood flow. The most important clinical effects are decreased sodium excretion, 
decreased potassium excretion and declines in renal perfusion. Decreased sodium 
excretion can result in weight gain, peripheral edema, attenuation of the effects of 
anti-hypertensive agents, and rarely precipitation of chronic heart failure. 
Hyperkalemia can occur to a degree sufficient to cause cardiac arrhythmias. Renal 
function can decline sufficiently enough to cause acute renal failure (Brater, 1999). 
These adverse renal effects tend to occur in patients who have some underlying 
condition, usually concomitant disease that places them at risk. This is particularly 
true for acute renal failure. Patients at risk for this complication are those who have 
either actual or effective circulating volume depletion. Other risk factors for adverse 
renal effects include preexisting hypertension, diabetes and in elderly patients with 
concomitant disease (Brater, 2002).  
Although the development of the COX-selective NSAIDs was based on the 
hypothesis that, by inhibiting only COX-2, these agents would be as efficacious as 
 5
nonselective NSAIDs yet have a reduced incidence of unwanted side effects, reports 
have revealed that these COX-2-selective inhibitors exhibit the same renal effects as 
nonselective NSAIDs (Brater, 1999 & 2002; Furst, 1997; Perazella and Tray, 2001), 
which has become a confusing issue for clinicians treating patients with underlying 
renal insufficiency. Despite the fact that COX-2 is primarily responsible for the 
prostanoid synthesis that mediates the propagation of inflammation, pain and fever, 
accumulating evidence suggests that COX-2 is also expressed constitutively in a few 
organs including the brain and kidney (Vane et al., 1998). Basal levels of COX-2 
have been located in the macula densa, thick ascending limbs and papillary interstitial 
cells of rats and in the glomerular podocytes and small blood vessels of humans 
(Khan et al., 1998). Since COX-2 is important in renal prostaglandin I2 (PGI2) 
synthesis, it implies that COX-2-selective inhibitors would have the same effects on 
renal function as conventional NSAIDs. Indeed, two COX-2-selective inhibitors – 
celecoxib and rofecoxib, have been shown to cause sodium retention and decrease 
glomerular filtration rate (GFR) to a similar extent as non-selective NSAIDs (Brater, 
2002).  
 
 Although COX-2-selective NSAIDs do not seem to spare the kidneys from 
adverse side effects, they do exhibit a good safety and efficacy profile with some 
indication of increased GI safety over several other conventional NSAIDs (Ahmed et 
al., 2005; Distel et al., 1996; Barner, 1996). The MELISSA study, a double-blind, 
randomized clinical trial showed that meloxicam caused statistically less total GI 
toxicity, dyspepsia, abdorminal pain, nausea and vomiting, and diarrhea than 
diclofenac, despite equivalent reductions in pain on movement for each treatment. 
Another global safety analysis of clinical trials showed that meloxicam caused less GI 
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toxicity and fewer peptic ulcers and GI bleeds than naproxen, diclofenac and 
piroxicam (Furst, 1997). In short, these studies showed that the COX-2-selective 
NSAIDs exhibit improved GI tolerability profile, albeit their renal safety profile is 
equivalent to other nonselective NSAIDs.  
 
1.3 Nephrotoxicity of diclofenac and meloxicam 
The adverse drug effects associated with NSAIDs are of particular concern when 
continuous NSAID therapy is needed, such as in treatment of various rheumatological 
disorders. Diclofenac and meloxicam are widely used for the reduction of 
inflammation and pain associated with arthritis and other conditions such as 
rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gouty arthritis 
(Brogden et al., 1980; Davies and Skjodt, 1999). Although the use of NSAIDs does 
not alter the course of the underlying disease, they have been found to relieve pain, 
reduce fever, swelling and tenderness, and increase mobility in patients with 
rheumatic disorders.  
 
Like other NSAIDs, gastrointestinal complications are the most common adverse 
effects of diclofenac. Occasionally, diclofenac causes a rare but potentially severe 
liver injury, which may be due to its bioactivation leading to the formation of reactive 
metabolites (Gόmez-Lechόn et al., 2003; Cantoni et al., 2003). Although the true 
scenario behind initiation of liver injury process remains unknown, many clinical 
studies reveal a variety of immune and non-immune mechanisms contribute towards 
the development of toxicity (Boelsterli, 2003). Despite the presence of numerous 
reports on liver toxicity of diclofenac, the renal effect of this drug should not be 
overlooked. In fact, Hickey et al. (2001) had found that the diclofenac-induced 
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nephrotoxicity occurred at a time when the liver damage was undetected, implying 
that hepatic events were not involved during the evolution of kidney injury. Moreover, 
diclofenac had been reported to be the main culprit of the death of vulture in Pakistan 
as a result of renal failure (Oaks et al., 2004; Proffitt and Bagla, 2004; Shultz et al., 
2004). According to Oaks et al. (2004), the dramatic loss of more than 95% of the 
vulture population from 1992 coincided with the introduction of diclofenac in the feed 
of livestock over the same period. Vultures in the laboratory fed diclofenac exhibited 
similar acute renal failure. It was concluded that the massive scale of diclofenac 
poisoning was due to the fact that this drug was concentrated in the kidney and liver 
of domestic livestock, and vultures fed on these organs of the carcasses. Post-mortems 
on the affected vultures showed kidney failure with accumulation of uric acid in the 
visceral organs (Oaks et al., 2004). To-date the mechanism of killing of vultures 
remains unknown although the kidney appears to be the main target. A literature 
search on diclofenac-induced toxicity associated with acute renal failure in humans 
retrieved a number of isolated cases (Stiefelhagen, 2004; Rubio Garcia and Tellez 
Molina, 1992; Cicuttini et al., 1989; Schwartz et al., 1988; Shohaib, 2000; Kulling et 
al., 1995; Rossi et al., 1985). Diclofenac also damages the kidneys of rainbow trout 
and rabbits (Schwaiger et al, 2004; Triebskorn et al., 2004; Taib et al., 2004). 
Ingested diclofenac residues were found to be more concentrated in the kidneys of 
buffalo and goat compared to their respective livers by a factor of 4, and its bio-
accumulation in the kidneys of the affected vultures was also noted (Oaks et al., 2004). 
Altogether, diclofenac seems to have more adverse effects on the kidneys in various 
animals including human.  
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With regard to the veterinary use of diclofenac that resulted in the decline of 
vulture population to the most severe category of global extinction risk, Swan et al. 
(2006) had carried out a study to seek potential alternative NSAIDs and they found 
that meloxicam is less toxic to the vultures. They hence suggested the use of 
meloxicam in place of diclofenac to reduce the mortality of vultures in the Indian 
subcontinent. Coincidently, another study by Harirforoosh and Jamali (2005) using rat 
also showed that meloxicam had no significant effect on either sodium and potassium 
excretion or on the urine flow rate while diclofenac significantly reduced the 
excretion rate of sodium and potassium. Nevertheless, clinical trials showed that the 
renal safety profile with meloxicam is equivalent to other NSAIDs including 
diclofenac. This difference in species susceptibility to NSAID-related renal toxicity 
could be explained by the significant interspecies differences in the expression and 
distribution of COX isoforms (Khan et al., 1998). Sellers et al. (2005) also reported 
that the basal expression of renal COX-2 varies among species, with high basal levels 
of COX-2 in the renal cortex and papilla in dogs compared with monkeys, thus lead to 
distinct nephrotoxic responses after COX-2 inhibition.     
 
1.4 Susceptibility of the kidney to toxic injury 
The adverse effects of drugs on kidneys are not surprising because when 
compared with other organs, the kidney is uniquely susceptible to chemical toxicity, 
partially due to its disproportionately high blood flow. Kidneys receive about 20 to 25 
percent of the resting cardiac output and hence any drug in the systemic circulation 
will be delivered to this organ in relatively high amounts. The processes involved in 
forming concentrated urine also serve to concentrate potential toxicants in the tubular 
fluid (Schnellmann, 2001). As water and electrolytes are reabsorbed from the 
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glomerular filtrate, drugs in the tubular fluid maybe concentrated, thereby driving 
passive diffusion of toxicants into tubular cells. As the consequence, a non-toxic 
concentration of a drug in the plasma may reach toxic concentrations in the kidney 
(Schnellmann, 2001). Moreover, the kidney is also known to be sensitive to 
circulating vasoactive substances including NSAIDs. NSAID-induced acute renal 
failure may occur which is characterized by decreased renal blood flow and 
glomerular filtration rate due to the inhibition of vasodilator prostaglandins (Brater, 
2002). Finally, renal transport, accumulation and metabolism of xenobiotics also 
contribute to the susceptibility of the kidney to toxic injury (Hickey et al., 2001).  
 
1.5 Mechanism of NSAID-induced nephrotoxicity 
Despite extensive studies on the toxicity of NSAIDs on various organs, the 
mechanism of NSAID-induced renal injury has not been completely clarified. It has 
been suggested that NSAID-induced mitochondrial injury might play an important 
role (Moreno-Sanchez et al., 1999; Krause et al., 2003; Mahmud et al., 1996; 
Mingatto et al., 1996). The suggestion is derived from the topical toxicity hypothesis 
(Somasundaram et al., 1997) which proposed that GI damage is initiated by the 
accumulation of NSAIDs in cells of the GI lining, with subsequent impairment of 
mitochondrial energy metabolism including uncoupling and/or inhibition of oxidative 
phosphorylation. However, the topical effect alone is not sufficient to cause GI 
toxicity as drugs with excellent GI safety profiles sometimes have a significant 
capacity for uncoupling and topical toxicity (Krause et al., 2003).  
 
Diclofenac has been reported by Uyemura et al. (1997) to be able to cause 
swelling of rat kidney mitochondria by inducing the membrane permeability transition 
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pore (MPTP). In parallel, Mingatto et al. (1996) claimed that diclofenac interfered 
with the respiration of rat kidney mitochondria by uncoupling oxidative 
phosphorylation and inhibiting the rate of ATP biosynthesis. Another in vivo study by 
Hickey et al. (2001) suggested that diclofenac-induced nephrotoxicity may involve 
production of reactive oxygen species leading to oxidative stress and massive 
genomic DNA fragmentation, which ultimately translate into apoptotic cell death of 
kidney cells. Compared to diclofenac, study on meloxicam is limited with only one 
report suggesting that meloxicam behaves as an uncoupler by stimulating basal 
respiration, inhibiting ATP biosynthesis and depressing mitochondrial membrane 
potential (Moreno-Sanchez et al., 1999).  
 
1.6 Role of mitochondria in drug-induced cell death 
The mitochondrion as the prime target of drug toxicity is not unexpected since this 
organelle has a central function in cellular energy production and it participates in 
multiple metabolic pathways. Among the various metabolic pathways, the respiratory 
chain and β-oxidation of fatty acids are frequent targets of mitochondrial toxins.  
According to Krähenbühl (2001), some well defined principal mechanisms for drug-
induced mitochondrial toxicity are inhibition of electron flow across electron transport 
chain, uncoupling of oxidative phosphorylation, opening of mitochondrial 
permeability transition pore (MPTP), inhibition of mitochondrial fatty acid 
metabolism, oxidation of mitochondrial DNA and inhibition of mitochondrial DNA 
synthesis. Given that mitochondrial oxidative processes are vital in the maintenance 
of cellular energy supply, any disruption of mitochondrial energy production can lead 
to serious consequences for the viability of the cell.  
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The role of mitochondria as a regulator in apoptosis and necrosis has also been 
widely studied (Kroemer et al., 1998; Lemasters et al., 1999). Kroemer et al. (1998) 
proposed that the choice between apoptosis and necrosis was determined by the 
severity of the mitochondrial permeability transition pore (MPTP); massive induction 
of MPTP with subsequent rapid depletion of energy-rich phosphates and the 
disruption of plasma membrane integrity causes necrosis while a regulated induction 
of MPTP allows for the activation and action of proteases and thus giving rise to the 
apoptosis phenotype. On the other hand, Lemasters et al. (1999) suggested that the 
progression to necrotic and apoptotic cell killing depends in part on the effect the 
MPTP has on cellular ATP levels. If ATP levels fall profoundly, necrotic killing 
ensues; if ATP levels are at least partially maintained, apoptosis follows the MPTP. In 
addition to MPTP per se, other mitochondrial proteins including cytochrome c and 
apoptosis-inducing-factor (AIF) play crucial role in cell death as well. Another class 
of mitochondrial proteins which is cell death regulator is the family of Bcl-2-related 
proteins. Bcl-2 belongs to a growing family of apoptosis-regulatory gene products that 
may be either death antagonists (e.g. Bcl-2, Bcl-XL) or death agonists (e.g. Bax, Bak, 
Bad).  
 
1.7 Aims of the project 
In the present study, the toxic effects of diclofenac and meloxicam on renal cells 
were studied, as kidney seems to be more susceptible than liver in terms of acute 
toxicity (Hickey et al, 2001). In order to compare the cytotoxicity of diclofenac and 
meloxicam in renal cells, LLC-PK1 and MDCK II cells were used; which former cell 
line is a proximal tubular cell line while the latter is a distal tubular cell line. The 
LLC-PK1 cell line is a continuous cell line derived from the proximal tubule of the pig 
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and has been widely used as a model system to study physiologic responses of the 
kidney proximal tubules. The toxicity of the two NSAIDs was studied with a focus on 
their mechanism(s) of cell death, to investigate if the meloxicam-induced cell death 
was different from that of diclofenac. Assessment of the effects of diclofenac and 
meloxicam on mitochondrial function was also carried out to investigate the effects of 
the drugs at subcellular level. The role of mitochondria in cell death was examined as 




















2. MATERIALS AND METHODS 
2.1 Chemicals 
Meloxicam, diclofenac, etoposide, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), adenosine 5’-triphosphate (ATP), adenosine 5’-
diphosphate (ADP), succinate, L-glutamic acid, L-malic acid, L-aspartate, 
oxaloacetate, α-ketoglutarate, N,N,N’,N’-tetramethyl-p-phenylenediamine (TMPD), 
L-ascorbic acid, β-nicotinamide adenine dinucleotide (NAD+), β-nicotinamide 
adenine dinucleotide reduced form (NADH), malate dehydrogenase (porcine heart, 
~700 units/mg protein), rotenone, antimycin A, oligomycin, sodium azide, 
decylubiquinone, amino-oxyacetate (AOA), FL-ASC Bioluminescent Somatic cell 
assay kit, Dulbecco’s Modified Eagle’s Medium (DMEM) and all other common 
chemicals were purchased from Sigma Aldrich (St. Louis, MO, USA). Aspartate 
transaminase (porcine heart, 200-500 units/mg protein) was from Fluka Chemie 
(Buchs, Switzerland). Medium 199, trypsin, penicillin-streptomycin and fetal bovine 
serum (FBS) were obtained from Gibco Life technologies. Annexin V-FITC, 
propidium iodide (PI) and 5,5’,6,6’-tetrachloro-1,1’,3,3’-
tetraethylbenzamidazolcarbocyanine iodide (JC-1) were from Molecular Probes Inc. 
(Eugene, OR, USA). Caspase-3 substrate (Ac-DEVD-AFC), caspase-9 substrate (Ac-
LEHD-AFC) and caspase-8 substrate (Ac-AEVD-AFC) were from Alexis 
Biochemicals. Mouse anti-cytochrome c monoclonal antibody was from BD 
Biosciences Pharmingen (Franklin Lakes, NJ, USA); goat anti-actin polyclonal 
antibody, rabbit anti-VDAC polyclonal antibody, and the secondary antibodies 
including horseradish peroxidase (HRP)-conjugated anti-mouse, anti-goat or anti-
rabbit IgG were from Santa Cruz Biotechnology (California, USA). ECL western 
blotting detection reagent was from GE Healthcare. The protein assay dye reagent and 
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polyvinylidene difluoride (PVDF) membranes were from Bio-Rad (Hercules, CA, 
USA).   
 
2.2 Isolation of rat kidney mitochondria 
Male Wistar rats (150-200 g) were starved overnight and killed by carbon dioxide 
exposure. Freshly excised kidney from a rat was washed in ice-cold isolation buffer 
containing 2 mM Tris-HCl, 250 mM sucrose, 4 mM potassium chloride, 2 mM EGTA 
and 0.4 g BSA (pH 7.5). The kidneys were cut into small pieces with scissors in about 
20 ml of the same isolation buffer and homogenized in a glass tube with a loose fitting 
Teflon-coated pestle using six upward and downward strokes. The homogenates were 
then centrifuged at 1000 x g for 10 min. The resulting supernatant was retained and 
further centrifuged at 10,000 x g for 10 min. The supernatant was discarded and the 
pellet was suspended in 1 ml of isolation medium. This was then diluted four times 
and centrifuged again at 10,000 x g for 10 min to obtain a clearer pellet. The final 
mitochondrial pellet was resuspended in 300 µl of the isolation buffer. The protein 
concentration was determined by the Bradford procedure (Bradford, 1976).  
 
2.3 Measurement of mitochondrial respiration by oxygen consumption 
Oxygen consumption was measured polarographically at 30°C with a Clark-type 
oxygen electrode (Hansetech) in a closed vessel equipped with a magnetic stirring bar. 
The incubation medium used to measure mitochondrial respiration consisted of 0.5 
mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH2PO4, 
20 mM Hepes, 110 mM sucrose and 1 g/L BSA (pH 7.1). The assay was initiated by 
adding a mitochondrial preparation containing 0.3 mg protein to the oxygraph cell 
containing the incubation medium. For the examination of the effect of 
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diclofenac/meloxicam on mitochondrial respiration, drugs at indicated concentrations 
were pre-incubated with the mitochondrial protein prior to the addition of respiratory 
substrates. After an equilibration period of about 5 min, succinate (10 mM) or 
glutamate/malate (5 mM each) was added and state-4 respiration was measured. 125 
µM ADP was then added to initiate state-3 respiration. Finally, 5 µg/ml of oligomycin 
was added to re-establish state-4 respiration. Respiratory control ratio (RCR) was then 
calculated as the ratio of state-3 to state-4 respiration and RCR values normally 
ranged from 4 to 6. 
 
2.4 Monitoring of mitochondrial membrane potential in isolated mitochondria by 
JC-1 
The mitochondrial membrane potential (MMP) was monitored by a change in the red 
peak, corresponding to the J-aggregates following the uptake of the fluorescent 
cyanine dye JC-1 into mitochondria, using a PerkinElmer LS55 luminescence 
spectrometer (Buckinghamshire, UK) as reported in Vincent et al. (2004), Zhang et al. 
(2004) and Ng et al. (2006).  The buffer used in this assay was medium A containing 
250 mM sucrose, 20 mM Hepes, 10 mM MgCl2 and 12.5 mM KH2PO4 (pH 7.1). 
After the addition of 0.2 µM JC-1 dye, 125 µM of ADP was added before the addition 
of a freshly prepared mitochondrial fraction containing about 0.2 mg protein. 
Succinate (10 mM) or glutamate/malate (5 mM each) was then added to further 
establish the maximal MMP. Various concentrations of diclofenac/meloxicam were 
then introduced after the establishment of the maximal MMP to examine any 
depolarisation induced by the drug; this is indicated by a decrease in the fluorescence 
of red aggregate with a reciprocal increase in the fluorescence of green monomers.  
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2.5 Biosynthesis of ATP in isolated mitochondria 
For the measurement of the rate of ATP biosynthesis in isolated mitochondria, the 
final volume was made up to 1 ml with the respiratory buffer containing 0.1 M KCl, 
12.5 mM KH2PO4 and 10 mM Tris-HCl (pH 7.6), 125 µM ADP and appropriate 
respiratory substrates with their respective inhibitors (Table 1). The reaction was 
started by adding a rat kidney mitochondrial preparation containing about 0.1 mg 
protein. After a 5-min incubation at 25°C, the reacted incubates were boiled for 3 min 
and centrifuged at 20,000 x g for 10 min. Suitable dilutions of the supernatant (50 x 
dilution) were made and 25 μl aliquots were taken for ATP determination following 
the procedure provided in the Sigma FL-ASC Bioluminescent Somatic cell assay kit. 
Measurements of the chemiluminescence of the luciferin-luciferase reaction were 
made using a 96-well plate and read in a luminometer (Victor3, PerkinElmer). The 
amount of ATP in each sample was extrapolated from a standard curve generated 




Table 1. Respiratory substrates and inhibitors used in the measurement of the 
rate of ATP biosynthesis in isolated kidney mitochondria. When ATP biosynthesis 
contributed by Complex II was examined, rotenone (Complex I inhibitor) was used to 
prevent the contribution of ATP biosynthesis from Complex I. Similarly, when ATP 
biosynthesis from Complex IV was of interest, upstream contribution was blocked by 
antimycin A (Complex III inhibitor).  
 










Succinate (10 mM) 
 




TMPD (1 mM) + ascorbate (5 mM) 
 
Antimycin A (4 µM) 




2.6 Measurement of NADH dehydrogenase (Complex I) activity 
The decrease of NADH fluorescence intensity due to the oxidation of NADH to 
NAD+ was measured fluorimetrically on a PerkinElmer LS55 luminescence 
spectrometer with Ex/Em of 352/464 nm. The reaction was carried out in an assay 
medium containing 25 mM KH2PO4, 5 mM MgCl2, 2 mg/ml BSA, 64 µM 
decylubiquinone, 2 mM sodium azide and 2 µg/ml antimycin A (pH 7.2). 100 μM 
NADH was first added and then the reaction was initiated by the addition of 0.3 mg of 
a mitochondrial extract.  The addition of 5 μM rotenone (Complex I inhibitor) was 
carried out as a positive control to demonstrate that the activity was specific to 
Complex I. The effect of diclofenac on Complex I was then investigated by replacing 
rotenone with 100 µM diclofenac. 
 
2.7 Measurement of glutamate dehydrogenase (GDH) and malate dehydrogenase    
(MDH) activities using mitochondrial extracts 
Glutamate dehydrogenase (GDH) and malate dehydrogenase (MDH) activities were 
measured by the change in fluorescence of NADH at Ex/Em of 352/464 nm in a 
microplate reader (Spectramax, Gemini XS, Molecular Devices) using extracts of 
isolated intact mitochondria containing 0.2 and 0.02 mg protein for the GDH and 
MDH assays, respectively (Williamson and Corkey, 1969; Heyde and Ainsworth, 
1968). Mitochondrial extracts were pre-incubated in the absence or presence of 10 - 
100 µM diclofenac prior to the initiation of the reaction. The concentrations of the 
substrates for the GDH assay are 10 mM α-ketoglutarate and 0.2 mM NADH for the 
forward reaction and 20 mM glutamate with 5 mM NAD+ for the reverse reaction. 
The MDH assay was carried out with 0.16 mM NADH and 0.4 mM oxaloacetate in 
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the forward, and 1 mM NAD+ and 5 mM malate in the reverse directions. Initial 
velocities were recorded for the first 5 min at room temperature.  
 
2.8 Measurement of malate-aspartate shuttle activity 
The activity of the malate-aspartate shuttle was determined using the method 
previously described by Scholz et al (1998) with some modifications (Ng et al., 2006). 
The buffer contained 300 mM mannitol, 10 mM KH2PO4, 10 mM Tris, 10mM KCl, 5 
mM MgCl2 and 2 mM aspartate (pH 7.4). 2 ml of the buffer was first mixed with 2 
mM ADP, 35 μM NADH, 3 U/ml MDH and 2 U/ml AST. A mitochondrial extract 
containing 0.1 mg of protein was then introduced and the baseline oxidation of 
NADH was measured fluorimetrically on a PerkinElmer LS55 luminescence 
spectrometer with Ex/Em of 352/464 nm at 37°C for 4 min. Malate-aspartate shuttle 
activity was initiated with the addition of 5 mM malate and 5 mM glutamate, and the 
oxidation of NADH was monitored for 4 min. The difference between the rate of 
change of fluorescence with and without added substrates was normalized with 
respect to mitochondrial protein used to determine the shuttle activity. To investigate 
the effect of diclofenac, various concentrations of diclofenac were added together 
with mitochondria prior to the addition of glutamate/malate. Amino-oxyacetate (AOA) 
which inhibits transaminase was used as a positive control for the inhibition of the 







2.9 Measurement of intra-mitochondrial NAD(P)H generated from 
glutamate/malate  
The basal NAD(P)H was measured in a PerkinElmer LS55 luminescence 
spectrometer at Ex/Em of 352/464 nm upon the addition of a preparation of intact 
kidney mitochondria containing 0.3 mg protein in a buffer containing 125 mM KCl, 
20 mM Hepes, 2 mM KH2PO4, 1 mM MgCl2, 0.25 mM EGTA and 0.5 mg/ml BSA 
(pH 7.0). Mitochondria were pre-incubated with 2 µg/ml of oligomycin to inhibit F1F0 
ATPase. With this inhibition, respiration in tightly coupled mitchondria was also 
inhibited. The change in auto-fluorescence of NAD(P)H attributed to the uptake of 
glutamate/malate (5 mM each) was monitored and compared to those in aliquots of 
mitochondrial preparation which had been pre-incubated with 5 – 50 µM of 
diclofenac for 5 min. The amount of NAD(P)H produced was extrapolated from a 
standard curve containing 2 – 10 nmol of NADH which showed a linear response. 
The stock solutions of glutamate and malate were prepared in Tris-HCl and adjusted 
to pH 7.1 to minimize their background fluorescence.  
 
2.10 Mammalian cell culture 
The Madin-Darby canine kidney (MDCK type II) cells were a gift from Dr. Walter 
Hunziker of Institute of Molecular and Cell Biology, Biopolis, Singapore. These cells 
were cultured in DMEM containing 100 U/ml each of penicillin G and streptomycin 
and 0.25 µg amphotericin B supplemented with 10% FBS in a humidified incubator 
with 5% CO2 at 37ºC. The LLC-PK1 cell line of porcine kidney origin was purchased 
from the American Type Culture Collection (ATCC, Manassas, VA, USA) and were 
maintained in medium 199 supplemented with 3% FBS, 100 U/ml each of penicillin 
and streptomycin under standard conditions. 
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2.11 Cell treatment with drugs 
Depending on the experimental needs, cells were seeded onto 96-well plates (1.5 x 
104 cells in 200 µl of media/well), 24-well plates (2 x 105 cells in 1 ml of media/well), 
or T25 cell culture flasks (1.5 x 106 cells in 5 ml of media/flask), and incubated 
overnight until a monolayer was formed. They were then incubated for varying time 
periods in the absence or presence of etoposide, meloxicam and diclofenac prepared 
in serum-free cell culture medium. Serum was excluded to avoid the interaction of the 
drugs with serum proteins as NSAIDs are highly protein-bound. Etoposide was used 
as a positive control for measurement of apoptosis. After the incubation with drugs, 
the cells were gently washed once with warm phosphate-buffered saline (PBS) and 
processed according to different experimental analyse. Each treatment was carried out 
in triplicates for statistical analysis.  
 
2.12 Phase-contrast microscopy 
The cellular morphology of treated and untreated cells was observed and 
photographed directly on their cell culture flasks using an inverted microscope (Zeiss, 
AXIOVERT 25 CFL) fitted with a digital camera (Nikon, CoolPix). The Zeiss 
AxiVision Software was used for viewing and processing of images. 
 
2.13 Assessment of cell viability 
 
Cells were grown overnight on 96-well plates. Freshly prepared MTT (0.5 mg/ml 
dissolved in cell culture medium) was added to each well and a 2-h incubation time 
was allowed. The amount of yellow MTT oxidised to purple formazan was then 
measured spectrophotometrically (A550nm) after the addition of 100 µl of DMSO into 
each well. The oxidation takes place only when mitochondrial reductase enzymes are 
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active, and thus conversion is directly related to the number of viable cells. The 
production of purple formazan in cells treated with various concentrations of drugs 
was measured relative to the production in untreated control cells and the cell viability 
was expressed as percentage of control (Mosmann, 1983).  
 
2.14 Measurement of intracellular ATP content 
Cells growing on 24-well plates were lysed with 50 µl of ice-cold lysis buffer (1 M 
Tris, pH 7.4, 5 M NaCl, 0.5 M EDTA, 0.1 M sodium vanadate, 1% Triton X-100 and 
1% NP-40) for 5 min on ice. The cells were then scraped off the plate and transferred 
into microfuge tubes. This was followed by boiling in a water bath for 3 min to 
inactivate any ATP hydrolytic activity present in the cell lysates. All samples were 
then spun at 20,000 x g for 10min at 4°C and the resulting supernatant was used 
immediately or kept at -80ºC for the quantification of ATP by means of the luciferin-
luciferase assay method as described in session 2.5.   
2.15 Measurement of caspase-3, -8 and -9 activities 
Cells growing in T25 cm2 cell culture flask were harvested by scraping using a rubber 
policeman and then spun down at 1000 rpm for 5 min. The cells were then lysed by 
the addition of lysis buffer containing 1 M Tris (pH 7.4), 5 M NaCl, 0.5 M EDTA, 0.1 
M sodium vanadate, 1% Triton X-100, 1% NP-40 and a cocktail of protease inhibitors. 
A 10-min incubation on ice was allowed before the samples were centrifuged at 
20,000 x g at 4°C for 10 min to remove cellular debris. The supernatants were 
collected and used as cell lysates for the determination of caspase activity. The 
reaction buffer for caspase activity determination was composed of 10 mM Hepes, 2 
mM EDTA, 10 mM KCl, 1.5 mM MgCl2, 4 mM DTT and a cocktail of protease 
 22
inhibitors. The reaction was started by the addition of  5 µl of fluorogenic substrates 
(Table 2) into 40 µl each  of cell lysate and reaction buffer and the fluorescence was 
monitored at Ex/Em of 400/505 nm for 1 h at 5 min intervals using a microplate 
reader (Spectramax, Gemini XS, Molecular Devices). Caspase activity was expressed 
as relative fluorescence units (RFU) per min per milligram protein and the final 
results were presented as percentage of control.  
 
Table 2. Fluorogenic substrates used in the determination of caspase activity. 
 
Caspases Fluorogenic Substrates Final concentration 
 














                    Ac-LEHD-AFC 
 
                 250 µM 
   
 
 
2.16 Annexin V-FITC/propidium iodide (PI) double staining 
Phosphatidylserine (PS) externalization was examined with a two-color analysis of 
fluorescein isothiocyanate (FITC)-labeled annexin V binding and PI uptake using 
flow cytometry. Annexin V-FITC labels externalized PS, which indicated apoptotic 
cell membrane disruption; while staining with PI indicated necrotic cells with cell 
membrane damage. The assay was performed according to the experimental protocol 
from the manufacturer (Vybrant Apoptosis Assay kit, Molecular Probes). Briefly, 
cells were harvested by trypsinization and washed once with ice-cold PBS, then 
resuspended in 500 µl of binding buffer (10 mM Hepes, 140 mM NaCl and 2.5 mM 
CaCl2 at pH 7.4). Cell density was determined and 100 µl of cell suspension 
containing 1 x 106 cells/ml was incubated with 5 µl of annexin V-FITC and 1 µl of PI 
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(100 µg/ml) for 15 min at room temperature in the dark. After the incubation period, 
400 µl of binding buffer was added to bring up the volume for the analysis on the 
flow cytometer (Beckman Coulter, Epics Altra) within 1 h. The stained cells were 
analyzed using 488-nm excitation and a 515-nm bandpass filter for fluorescein 
detection and a filter >580 nm for PI detection. A total of 10,000 cells were analyzed 
per tube, and data acquired in the list mode were processed using Win MDI 2.8 
software. The fluorescence distribution was displayed as dot plot analysis, and the 
percentage of fluorescent cells in each quadrant was determined. In order to exclude 
any emission spectra overlap, controls such as unstained cells, cells stained with 
annexin V-FITC only and cells stained with PI only were included. This method is 
used to discriminate between intact living cells (FITC-/PI-), apoptotic cells (FITC+/PI-) 
and late apoptotic/necrotic cells (FITC+/PI+) (Vermes et al., 1995; Schutte et al., 
1998). 
 
2.17 Preparation of cytosolic fractions for western blot analysis.  
Cytosolic protein extracts for measuring cytochrome c release were prepared as 
described (Yang et al., 1997). Briefly, untreated and treated cells from one 175-cm2 
flask were harvested by trypsinization, washed once in cold PBS, and resuspended in 
100 µl of ice-cold buffer A (20 mM Hepes-KOH, pH 7.5, 250 mM sucrose, 10 mM 
KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1mM DTT and a cocktail of 
protease inhibitors). The cells were lysed with 10 strokes using a dounce homogenizer. 
After homogenization, unbroken cells, large plasma membrane pieces and nuclei were 
removed by centrifugation at 800 x g for 10 min at 4°C. The supernatant was 
subjected to centrifugation at 10,000 x g for 15 min at 4°C and the resulting 
supernatant was further centrifuged at 100,000 x g for 1 h at 4°C to generate cytosolic 
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soluble fractions (S-100). The protein content of individual fractions was determined 
using the Bradford assay and the samples were kept at -80°C for western blot analysis.  
 
2.18 Western blot analysis 
Sample buffer (130 mM Tris-HCl, pH 8.0, 20% v/v glycerol, 4.6% w/v SDS, 0.02% 
bromophenol blue and 2% DTT) was added to the cytosolic fractions, which were 
subsequently boiled for 5 min and subjected to electrophoresis on a 15% SDS-
polyacrylamide gel (25 and 15 µg protein/lane for MDCK II and LLC-PK1 cells 
respectively). Separated proteins were then transferred to a polyvinylidene fluoride 
(PVDF) membrane using a mini Trans-blot cell system (BioRad). The membranes 
were then blocked by incubation with 5% skimmed milk prepared in PBST (PBS with 
0.1% Tween-20) for 1 h at room temperature. The membranes were then incubated 
with a mouse monoclonal anti-cytochrome c antibody, a rabbit anti-VDAC antibody, 
or a goat anti-actin antibody; each antibody was diluted 1000 times. After three 
washes (15 min each) with PBST, the membranes were incubated with appropriate 
horseradish peroxidase (HRP)-conjugated secondary antibody for 1 h at room 
temperature. Finally, the membranes were washed again before incubated with 
detection reagent and exposed to X-ray films. The amount of cytochrome c protein 








2.19 Statistical analysis 
The significance of the differences between drug-treated and respective controls was 
determined using the Student’s t-test. Values were expressed as the mean ± standard 
deviation (SD), and were calculated from three independent experiments. A value of 
P < 0.05 was considered statistically significant, and represented by asterisks: *, P < 





































3.1 Action of diclofenac and meloxicam on kidney mitochondrial function   
 
3.1.1    Uncoupling of oxidative phosphorylation 
The in vitro interference of diclofenac and meloxicam with the respiration of rat 
kidney mitochondria was evaluated for glutamate plus malate (complex I substrates) 
and succinate (complex II substrate) oxidation (Fig. 2). Mitochondria were pre-
incubated with various concentrations of the drugs and their effects on state-4 and 
state-3 respiration were studied. For succinate oxidation, both diclofenac and 
meloxicam at 50 µM stimulated state-4 respiration (after the addition of oligomycin) 
but depressed state-3 respiration (after the addition of ADP) of mitochondria (Fig. 2A 
and C). This resulted in a decrease in the respiratory control ratio (RCR) after drug 
treatment as RCR was calculated as the ratio of state-3 over state-4 respiration. The 
effects of diclofenac and meloxicam on mitochondrial respiration for glutamate plus 
malate oxidation were closely similar to those observed for succinate oxidation (Fig. 
2B and D). These results showed that diclofenac and meloxicam were acting as 
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Fig. 2. Effect of diclofenac (A, B) and meloxicam (C, D) on mitochondrial 
respiration using succinate (A, C) or glutamate/malate (B, D) as substrates. 
Mitochondria (0.3 mg protein) and drugs were pre-incubated for 5 min before starting 
respiration by the addition of respiratory substrates. State-3 and state-4 respiration 
were induced with 125 µM ADP and 5 µg/ml oligomycin, respectively. The Arabic 
numbers in each figure represent the rate of respiration as expressed in nmol/min/mg 
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3.1.2    Loss of mitochondrial membrane potential (MMP) 
Since uncouplers affect the electrochemical gradient across the inner 
mitochondrial membrane, the ability of diclofenac to decrease the MMP generated by 
mitochondrial respiration was investigated. Uptake of JC-1 into mitochondria isolated 
from freshly excised kidneys was demonstrated by an increase in the green 
fluorescence of the monomers (shown by dotted lines in Fig. 3) with concomitant 
formation of the J-aggregates represented by an increase in the red fluorescence. 
Upon addition of succinate (Fig. 3A and C) or glutamate plus malate (Fig. 3B and D), 
an immediate sharp increase in MMP was reflected by the higher intensity of the red 
fluorescence signal with a reciprocal decrease in the green fluorescence. The 
established MMP was maintained for about 8-10 min. Addition of diclofenac (Fig. 3A 
and B) or meloxicam (Fig. 3C and D) depressed the MMP in a dose-dependent 
manner.  This was shown by the decrease in red fluorescence with a reciprocal 























































































Fig. 3. Action of diclofenac (A, B) and meloxicam (C, D) on mitochondrial 
membrane potential measured with JC-1 in rat kidney mitochondria. A 
reciprocal relationship between the fluorescence of the red aggregates of JC-1 
(expressed as relative fluorescence units or RFU) and that of the green monomers 
(shown by dotted lines) was consistently observed although only a representative 
trace for one concentration of diclofenac/meloxicam is shown for each figure. 
Succinate (10 mM) or glutamate plus malate (5 mM each) were used to energize the 
mitochondrial membrane potential. The collapse of MMP by diclofenac and 
meloxicam displayed a dose-dependent pattern. 
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3.1.3    Inhibition of ATP biosynthesis 
The effects of diclofenac and meloxicam on the rate of ATP biosynthesis in rat 
kidney mitochondria were evaluated for glutamate plus malate (Complex I), succinate 
(Complex II) and TMPD/ascorbate (Complex IV) oxidation (Fig. 4). Inhibition of 
ATP biosynthesis by diclofenac and meloxicam was concentration-dependent 
between 5 and 50 µM when glutamate plus malate were used as the respiratory 
substrates. It was worth noting that the effect of diclofenac was more pronounced than 
meloxicam in inhibiting the rate of ATP biosynthesis from glutamate plus malate 
oxidation. However, with succinate and TMPD/ascorbate as the oxidizable substrates, 
at least 50 µM of diclofenac was required to produce a significant decrease which was 
much smaller in magnitude when compared to glutamate plus malate oxidation. 
Interestingly, with succinate and TMPD/ascorbate as the oxidizable substrates, 
meloxicam inhibited the rate of ATP biosynthesis in a manner not dissimilar from that 
observed in the ATP biosynthesis from the oxidation of glutamate plus malate. In 
other words, meloxicam inhibited the rate of ATP biosynthesis to a similar extent 
regardless of the substrates being used while diclofenac inhibited preferentially the 







































































Fig. 4. Effect of diclofenac (A) and meloxicam (B) on the rate of ATP 
biosynthesis by rat kidney mitochondria. ATP produced from the oxidation of 
glutamate/malate, succinate or TMPD/ascorbate in the absence or presence of 5 - 50 
µM of diclofenac or meloxicam was determined. Values are means ± SD (n = 3). * P 






3.1.4    Effect of diclofenac on NADH dehydrogenase (Complex I) activity 
Complex I of the respiratory chain was suspected to be the target of the action of 
diclofenac since a significant inhibition of ATP biosynthesis was observed when 
Complex I substrates were used (Fig. 4A). Therefore, the direct effect of diclofenac 
on NADH dehydrogenase was investigated, using the rat kidney mitochondrial 
extracts. Rotenone being a specific inhibitor of Complex I was used as a positive 
control. A decrease in NADH fluorescence signal was observed immediately upon the 
addition of 5 µM of rotenone (Fig. 5A). Diclofenac however did not show any direct 













Fig.  5. Representative recordings of NADH dehydrogenase activity using rat 
kidney mitochondrial extracts. NADH dehydrogenase activity was monitored by a 
decrease in the fluorescence of NADH. (A) Upon addition of 5 µM rotenone (a 
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3.1.5 Effect of diclofenac on GDH and MDH activities 
The oxidation of glutamate and malate by their respective NAD-linked 
dehydrogenases in rat kidney mitochondrial extracts was also monitored by measuring 
the fluorescence of NADH. The effect of diclofenac on the enzyme activities was 
examined in both forward and reverse enzymatic reactions under appropriate 
experimental conditions. Fig. 6 showed that diclofenac at concentrations of 10 - 100 
µM did not inhibit either GDH or MDH activity. In the assay for the determination of 
GDH activity, GTP was included as a positive control to inhibit GDH activity (Lee et 
al., 2001).  




































































Fig.  6. Effect of diclofenac on (A) GDH and (B) MDH activities measured in 
both forward and reverse reactions.  The activities of GDH and MDH were 
measured by the decrease or increase in the NADH fluorescence using microplate 
reader. Diclofenac at 10 to 100 µM did not inhibit either GDH or MDH activity while 
GTP at 1 mM caused a drastic decrease in the GDH activity.  
 





3.1.6    Inhibition of malate-aspartate shuttle by diclofenac 
In kidney, the entry of glutamate/malate into mitochondria mainly depends on 
the malate-aspartate shuttle. Since NADH dehydrogenase, glutamate dehydrogenase 
and malate dehydrogenase activities were unaffected by diclofenac, the malate-
aspartate shuttle became the next target for investigation. From the kinetics of the 
initial velocity of the malate-aspartate shuttle measured by the coupled assay in the 
reconstituted system (Scholz et al., 1988), it was apparent that 10 - 50 µM diclofenac 
inhibited the malate-aspartate shuttle significantly in a dose-dependent manner (Fig. 
7A). About 60% of the shuttle activity was inhibited by 50 µM of diclofenac. The 
positive control with 100 µM amino-oxyacetate (AOA), a known inhibitor of 
transaminase, showed almost complete inhibition under the same experimental 
conditions. A mixed type of inhibition on the malate-aspartate shuttle was concluded 
































































Fig. 7. Inhibition of the malate-aspartate shuttle by diclofenac. (A) The activity of 
the malate-aspartate shuttle was inhibited significantly by 10 - 50 µM of diclofenac. 
Amino-oxyacetate (AOA), a known inhibitor of transaminase, showed almost 
complete inhibition at 100 µM. Values are means ± SD (n = 3). * P < 0.05, ** P < 
0.01. (B) The Lineweaver-Burk plot of the initial velocity (v) of the malate-aspartate 
shuttle against the substrate concentration of 0.5 - 5 mM of glutamate plus malate was 
obtained in the absence (♦) or presence of 5 (■) and 50 (○) µM diclofenac. A mixed-
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3.1.7    Inhibition of the intra-mitochondrial production of NAD(P)H by  
diclofenac 
Inhibition of the malate-aspartate shuttle could affect the ability of the 
mitochondria to synthesize NAD(P)H as entry of malate and glutamate would be 
compromised. It was found that in isolated rat kidney mitochondria in the presence of 
oligomycin (to inhibit respiration via inhibition of F1F0 ATPase in coupled 
mitochondria), the NAD(P)H generated from 5 mM glutamate/malate was 
significantly lower when mitochondria were pre-incubated with 10 - 50 µM of 
diclofenac (Fig. 8). The concentrations of diclofenac that inhibited the production of 
intra-mitochondrial NAD(P)H were correlated with those that inhibited the malate-
aspartate shuttle activity. The RCR measured with glutamate/malate in this 
experiment approximates 6.0. The concentrations of diclofenac employed did not 











Fig. 8. Measurement of intra-mitchondrial NAD(P)H in rat kidney mitochondria. 
A progressive decrease in NAD(P)H generated from 5 mM glutamate/malate was 
apparent when isolated intact kidney mitochondria (0.3 mg protein) were pre-
incubated with 5 - 50 µM diclofenac compared to control. Addition of 2 µg/ml 
oligomycin was employed to inhibit the F1F0 ATPase which would arrest respiration 
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3.2 Studies with cultured kidney cell lines – MDCK II and LLC-PK1 
3.2.1    Drug effects on cell viability 
Cells were incubated with increasing concentrations of diclofenac or meloxicam 
for varying time points and the cytotoxicity was measured by the MTT reduction 
assay. It was found that the cell viability was minimally affected at 10 and 50 µM of 
meloxicam and diclofenac, but was compromised when MDCK II and LLC-PK1 cells 
were exposed to 250 and 500 µM of meloxicam (Fig. 9A and C) and diclofenac (Fig. 
9B and D) for 12 and 24 h.  From Fig. 8 it was evident that diclofenac was more toxic 
than meloxicam and this was demonstrated in both cell lines. The effects of both 
drugs were found to be more pronounced in LLC-PK1 than in MDCK II cells. This 




Fig. 9. Effects of meloxicam and diclofenac on cell viability. MDCK II cells (A and 
B) and LLC-PK1 cells (C and D) were exposed to increasing concentrations of 
meloxicam and diclofenac and cell viability was assessed by the MTT assay. Results 
were compared to their respective untreated controls and presented as percentage cell 
viability. Data points are means ± SD (n = 3). The concentrations of the drugs were (■) 














































































3.2.2 Effects of etoposide, meloxicam and diclofenac on the cellular                       
morphological changes 
The morphological alterations in MDCK II cells were apparent after 6 h of 
incubation with etoposide, meloxicam and diclofenac (Fig. 10B, C and D, 
respectively) compared to untreated control (Fig. 10A). A small population of cells 
showed rounded morphology (indicated by arrow heads). Following exposure to 
etoposide and meloxicam for 12 h, disaggregation of the cell monolayer with cellular 
detachment from the culture flasks was observed. The detached spherical cells formed 
apoptotic bodies which appeared to float in the media (Fig. 10B and C, indicated by 
arrows); this is a hallmark of apoptotic cell death. Later at 24 h time point, almost all 
of the etoposide- and meloxicam-exposed cells were detached from the flasks and 
secondary necrosis ensued. On the other hand, the cell density of diclofenac-treated 
cells at 12 h was sparse and the cells had lost their normal morphology (Fig. 10D). 
The remnants of diclofenac-treated cells remained attached to the flasks at 24 h, with 
less evidence of apoptotic bodies as was the case of etoposide- and meloxicam-treated 
cells. 
 
Confluent monolayers of LLC-PK1 cells have irregular form with well defined 
intercellular limits (Fig. 11A). “Dome-like” structures which project upwards from 
the bottom of the culture flasks were observed (bold arrow).  These structures are 
indicators of transepithelial transport of solutes in vitro and therefore, they represent a 
functional epithelium (Handler, 1983). Morphological changes were characterized by 
the presence of numerous dark particulates between cells and on cell surfaces and the 
cell boundaries became less distinct after 3 and 6 h of incubation with meloxicam and 
diclofenac (Fig. 11C and D, respectively). These black particles appeared to represent 
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discharged cellular contents giving the cells a “contaminated” appearance. Later at 12 
h, clumps of dead cells were observed floating in the media. For etoposide-treated 
cells (Fig. 11B), rounded morphology was observed at 12 h time point (indicated by 
arrow heads) as well as the appearance of the black particulates, although to a much 







Fig. 10. Morphological changes of MDCK II cells following drug exposure. (A) 
Untreated cells showed polygonal shape with their intercellular unions clearly 
delimited. Untreated cells at 0 h have features similar to those observed at 6 h and 
were therefore not shown. (B, C) Apoptosis was induced in etoposide- and 
meloxicam-treated cells as shown by the initial formation of rounded cells (shown by 
arrow heads) which eventually become apoptotic bodies (shown by arrows). (D) 
Diclofenac induced the formation of rounded cells during early exposure but the cells 
seemed to die via necrosis after an extended period as shown by the attachment of cell 














Fig. 11. Morphology of LLC-PK1 cells following drug exposure. (A) Cells in 
confluent cultures showed well-defined intercellular limits and it was possible to 
observe “domes” identified by an arrow. (B) Cells treated with etoposide showed 
rounded morphology (arrow heads) at 12 h time point. (C, D) Meloxicam- and 
diclofenac-treated cells looked “contaminated” due to the cellular discharge into 
culture media. Cell boundaries became blurred but the cells were still attached to the 
flasks. The cells eventually clumped together and floated in the media (> 12 h).  
Images were visualized by phase contrast microscope and all photographs were taken 
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3.2.3    Activities of caspase-3, -8 and -9 
Caspases, a family of cysteine proteases, are well-known molecular executioners 
of apoptosis as they bring about most of the morphological and biochemical 
characteristics of apoptotic cell death (Padanilam, 2003). To characterize the 
execution pathway of apoptosis, caspase-3, -8 and -9 activities were measured. A 
time-dependent increase in caspase-3 activity was observed in MDCK II cells treated 
with etoposide and meloxicam up to 12 h (Fig. 12A), when the activity reached a 
maximum and decreased thereafter. The changes were less pronounced for diclofenac, 
with only a 5-fold increase compared to 26- and 18-fold increases for etoposide- and 
meloxicam-treated cells, respectively. Caspase-9 activity displayed a similar profile as 
caspase-3 although the magnitude of change was smaller (Fig. 12B), implying the 
involvement of the intrinsic mitochondrial pathway. In contrast, the increase in 
caspase-8 activity was low for meloxicam with no change in diclofenac-treated cells 
implying that the caspase-8-associated death receptor pathway was unlikely to play a 
significant role in the meloxicam- and diclofenac-induced cell death in MDCK II cells 
(Fig. 12C). 
 
There was little to no change in caspase-3 activity for all drug-treated LLC-PK1 
cells at 3 h time point with only a small increase at 6 h for meloxicam- and 
diclofenac-treated cells (Fig. 13). Etoposide treatment elicited a modest increase (6 to 
7 folds) compared to the 16 to 26 folds produced in MDCK II cells (Fig. 12A). Since 
the magnitude of increase in caspase-3 activity was small, caspase-9 and -8 activities 




Fig. 12. Caspase activation by etoposide (Eto), meloxicam (Mel) and diclofenac 
(Dcf) in MDCK II cells. Lysates of cells exposed to the drugs were prepared for the 
measurement of activities of (A) caspase-3, (B) caspase-9 and (C) caspase-8. Caspase 
activity was expressed as Relative Fluorescence Unit (RFU) /min/mg protein. Results 
were expressed as percentage of control. Data points are means ± SD for n = 3 





























































































Fig. 13. Caspase-3 activity measured in LLC-PK1 cells. Caspase-3 activity was 
measured after the cells were exposed to etoposide (Eto), meloxicam (Mel) and 
diclofenac (Dcf) following the experimental conditions described in Fig. 12.  
 
  
3.2.4    Release of cytochrome c 
With regard to the intrinsic mitochondrial pathway, its execution requires the 
release of cytochrome c from mitochondria to the cytosol to form apoptosome with 
Apaf-1 and pro-caspase-9 (Liu et al., 1996). Immunoblot assays revealed the presence 
of cytochrome c in the cytosolic extracts of drug-treated MDCK II cells at 6 and 12 h 
(Fig. 14A). The cytosolic fractions were relatively free from mitochondrial 
contaminants as shown by the absence of the voltage-dependent-anionic channel 
(VDAC) protein; the latter was identified as a 30 kDa band in mitochondrial extracts 
obtained from rat liver (Fig. 14B). β-actin was used as a reference to normalize the 
proteins loaded. The amount of cytochrome c protein was quantified by the 
densitometric scanning of X-ray films and the results were shown in Fig. 14C. It was 
evident that the cytosolic cytochrome c was increased in a time-dependent manner in 
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the amount of the released cytochrome c was also lower after diclofenac treatment 
compared to etoposide and meloxicam treatment.  
 
In LLC-PK1 cells, the etoposide- and meloxicam-treated cells showed an 
increase in cytochrome c from 3 to 6 h and a decrease thereafter (Fig. 15A). In 
contrast, diclofenac-treated LLC-PK1 cells produced only a minimal release of 
cytochrome c at 6 h time point which was not detectable at either 3 or 12 h. The 
quantitative measurement of the cytochrome c using densitography was shown in Fig 
15B. Comparing the two cell lines, cytochrome c release occurred at an earlier time 
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Fig. 14. Drug-induced release of cytochrome c in MDCK II cells. (A) Cytosolic 
protein extracts (25 µg protein per lane) obtained from untreated control cells (ctrl) 
and cells treated with 100 µM etoposide, 500 µM meloxicam or diclofenac for 0, 6 
and 12 h were used for immunoblot analysis of cytochrome c. Blots were also 
incubated with an anti-VDAC antibody to detect any contamination of outer 
mitochondrial proteins in the cytosolic fractions. (B) Samples did not contain VDAC 
protein. Lanes 1-4 were cytosolic fractions from untreated, etoposide-, meloxicam- 
and diclofenac-treated cells respectively; lane 5 was a mitochondrial extract obtained 
from rat liver. ß-actin was used for normalization of proteins in the samples. (C) 
Quantification of cytochrome c using densitometer. Cytochrome c release was greater 
in etoposide- and meloxicam-treated cells compared to cells exposed to diclofenac.  
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Fig. 15. Drug-induced release of cytochrome c in LLC-PK1 cells. (A) Cytosolic 
fractions (15 µg protein/lane) obtained from untreated control cells (ctrl) and cells 
treated with 100 µM etoposide, 500 µM meloxicam or diclofenac for 0, 3, 6 and 12 h 
were used for immunoblot analysis of cytochrome c. Blots were also incubated with 
an anti-VDAC antibody to detect any mitochondrial contamination in the cytosolic 
fractions. ß-actin was used to normalize loading of samples. (B) Quantification of 
cytochrome c using densitometer. Cytochrome c release was detected at 3- and 6-h 
post-drug treatment in etoposide- and meloxicam-treated cells but not in diclofenac-
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3.2.5    Effects of drugs on intracellular ATP level 
The activation of the apoptosome requires ATP as an essential co-factor (Liu et 
al., 1996). Moreover, ATP synthesis may be blocked as a consequence of meloxicam- 
and diclofenac-provoked uncoupling of oxidative phosphorylation as observed earlier 
(Fig. 2). For these reasons, the intracellular ATP level after drug treatment was 
determined. There was an initial increase of up to 40% in intracellular ATP from 0.5 
to 3 h in MDCK II cells exposed to etoposide, meloxicam and diclofenac, compared 
to the untreated controls, as shown in Fig. 16A. This early increase was followed by a 
decrease at 6 and 12 h.  
 
In contrast to MDCK II cells, there was no initial increase in intracellular ATP 
level in LLC-PK1 cells (Fig 16B). At 6 h, a decrease in intracellular ATP level was 
seen in cells treated with meloxicam and diclofenac at the concentration of 500 µM. 
From 12 h onwards, all drug-treated cells showed a dose- and time- dependent 
decrease in intracellular ATP level. It is worth noting that the decrease in intracellular 
ATP level, if any, was always more drastic for diclofenac-treated cells compared to 
meloxicam treated cells, thus suggesting that the insult from diclofenac is more severe 









Fig. 16. Intracellular ATP following drug exposure. (A) Cytosolic ATP in MDCK 
II cells was maintained at a level higher than control cells during the early stages (0.5 
to 3 h) of cell death induced by the incubation of cells with etoposide (Eto), 
meloxicam (Mel) and diclofenac (Dcf). (B) Cytosolic ATP showed no elevation in 
LLC-PK1 cells at all time points but a decrease from 6 to 24 h. Values are expressed 
as percentages of the corresponding untreated controls. Data are means ± SD of 



















































3.2.6 Externalization of phosphatidylserine (PS) and loss of plasma 
membrane integrity 
In the early stages of apoptosis, changes occur at the cell surface. One of the 
plasma membrane alterations is the translocation of PS from the inner to the outer 
layer of the plasma membrane (Schutte et al., 1998). Annexin V is a phospholipid-
binding protein with a high affinity for PS and hence it can be used as a sensitive 
probe for PS exposure detection (Vermes et al., 1995). In the present study, annexin 
V-FITC and propidium iodide (PI) double staining was carried out to quantify the 
frequency of cell death by apoptosis and necrosis, respectively. Viable cells are 
represented by doubly negative (FITC-/PI-) staining (lower left quadrant), while 
apoptotic cells are FITC+/PI- (lower right, R2, quadrant) and necrotic cells are doubly 
positively (FITC+/PI+) stained (top right, R1, quadrant).  
 
In MDCK II cells treated with etoposide, the FITC+/PI- apoptotic cell population 
increased from 18% at t = 6 h, to 40% after 12 h and to 48% after 18 h. (Fig. 17B). Of 
note, the population of viable cells decreased with a concomitant increase in the 
FITC+/PI+ necrotic cell population in etoposide-treated cells at t = 18 h, indicating that 
some of the apoptotic cells were undergoing secondary necrosis. Similar results were 
obtained from meloxicam-treated MDCK II cells, suggesting that these cells were 
undergoing apoptosis (Fig. 17C). For diclofenac-treated MDCK II cells, a remarkable 
increase in the percentage of FITC+/PI+ necrotic cells 18 h after drug exposure was 
observed (Fig. 17D). Moreover, the apoptotic cell population was always 
comparatively smaller with diclofenac treatment compared to etoposide and 
meloxicam treatment. Taken together, these results indicated that diclofenac-treated 
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MDCK II cells were more severely damaged as more cells had lost their membrane 
integrity after extended exposure to drug.   
 
Results obtained from LLC-PK1 cells showed a similar pattern except that the 
effect was observed earlier (Fig. 18 and 19), which concurred with the results of the 
cytochrome c release (Fig. 15). There was a gradual increase in the FITC+/PI- 
apoptotic cell population under all drug treatments. Diclofenac-treated cells showed a 
significant increase in the FITC+/PI+ necrotic cell population from 2% at t = 3 h, to 
26% after 6 h and to 42% after 12 h (Fig. 18D). Comparatively, meloxicam caused a 
milder increase in the percentage of necrotic cells, which was 18% and 32% after 6 
and 12 h, respectively (Fig. 18C). These results showed that diclofenac is more potent 
than meloxicam in causing necrotic cell death in LLC-PK1 cells.  Comparing the 
corresponding data of 6 and 12 h exposure, the necrotic effect was greater in the LLC-
PK1 cells compared to MDCK II cells, thus further confirmed the findings that LLC-
PK1 cell line was more susceptible to drug toxicity than MDCK II cell line. Of note, 
untreated MDCK II and LLC-PK1 cells showed a time-dependent increase in the 
percentage of FITC+/PI- apoptotic cells, possibly due to serum withdrawal, as reported 




























































































































































































































































































































































































































































































   
   
   




















































































































































































































































































































































































































































































































































































































    
   







   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   













































































































































































































































































































4.1 Studies in isolated kidney mitochondria 
4.1.1 Uncoupling of oxidative phosphorylation, decrease in mitochondrial 
membrane potential and inhibition of ATP biosynthesis 
Mitochondria, that play a crucial role in maintaining the cell ATP-dependent 
processes, are recognized as a potential target of drug-induced toxicity (Krähenbühl, 
2001). In fact, several studies have implicated mitochondrial damage in the toxic 
process initiated by various NSAIDs (Mingatto et al., 1996; Mahmud et al, 1996; 
Krause et al., 2003; Moreno-Sanchez et al, 1999). Since mitochondrial respiratory 
processes contribute mainly to the ATP requirements in a cell, an impairment of 
mitochondrial respiration would be reflected in a lowering of ATP levels. Any 
compromise in the ATP biosynthetic process is detrimental to cells as ATP is needed 
to drive many energy-dependent processes and the extent of ATP depletion 
determines if a cell undergoes apoptosis or necrosis. 
 
There are several ways in which mitochondrial dysfunction could lead to a 
decrease in ATP biosynthesis. One of them is the uncoupling of oxidative 
phosphorylation, which is a phenomenon when protons leak back into the matrix 
without going through the ATP synthase. Thus the electrochemical gradient across the 
membrane is dissipated without generating ATP. Uncoupling of oxidative 
phosphorylation results in increased oxygen consumption and heat production as 
electron flow and proton pumping attempt to maintain the electrochemical gradient. In 
the present study, the uncoupling effect of diclofenac and meloxicam on isolated 
kidney mitochondria was investigated by measuring the state-3 and state-4 respiration. 
State-3 respiration refers to the actively respiring state when the addition of ADP 
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causes a sudden burst of oxygen uptake as the ADP is converted to ATP; state-4 
respiration refers to the basal state after all the ADP has been phosphorylated to form 
ATP. The respiratory control ratio (RCR) indicates the tightness of the coupling 
between respiration and phosphorylation and therefore a decrease in RCR value 
implicates uncoupling of oxidative phosphorylation. Both diclofenac and meloxicam 
were found to stimulate the rate of state-4 respiration but depress the rate of state-3 
respiration, thus resulted in a decrease in the RCR values. This observation concurred 
with the previous findings which showed that diclofenac and/or meloxicam caused 
mitochondrial dysfunction by acting as an uncoupler (Mingatto et al., 1996; Moreno-
Sanchez et al., 1999; Mahmud et al., 1996; Krause et al., 2003).   
 
Uncouplers also known as proton ionophores, are lipid-soluble compounds that 
rapidly transport protons from the cytosolic to the matrix side of the inner 
mitochondrial membrane. Because the proton concentration is higher in the 
intermembrane space than in the matrix, uncouplers pick up protons from the 
intermembrane space. Their lipid solubility enables them to diffuse through the inner 
mitochondrial membrane while carrying protons and release these protons on the 
matrix side. During the process of this futile proton cycling, the electron transport 
chain can be stimulated in an attempt to compensate for the gradient loss, and 
therefore resulted in an increase in state-4 respiration when oxygen consumption is 
measured. However, the state-3 respiration is reduced as protons returned randomly 
across the inner mitochondrial membrane instead of being transported through the F0 
portion of ATP synthase. As a consequence, the respiratory control ratio is decreased 
which was observed in the present study. The mechanism of action of uncoupler is 
 63
demonstrated by 2,4-dinitrophenol (DNP), which is a well-known uncoupler, and 
shown in Fig 20.  
 
Fig. 20. Uncoupling of oxidative phosphorylation by 2,4-dinitrophenol DNP.  
  
The rapid influx of protons into the matrix stimulated by uncouplers could 
dissipate the electrochemical potential gradient and resulted in the decrease in 
mitochondrial membrane potential (MMP). Consequently, the mitochondria are 
unable to synthesize ATP at a normal rate. According to Moreno-Sanchez et al. 
(1999), three parameters have to be assessed together to unambiguously distinguish 
uncouplers from respiratory inhibitors, namely the respiration rate, the MMP and ATP 
biosynthesis. Therefore, in addition to the measurement of the oxygen consumption, 
the effects of diclofenac and meloxicam on MMP and ATP biosynthesis were further 
examined. Results from the current study showed that the MMP measured by the JC-1 
probe as well as the rate of ATP biosynthesis were compromised by diclofenac and 
meloxicam in isolated kidney mitochondria. Nonetheless, while meloxicam inhibited 
  ATP synthase 
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ATP biosynthesis with comparable strength during the oxidation of either complex I, 
II or IV substrates, diclofenac inhibited strongly the rate of ATP biosynthesis during 
complex I substrate oxidation but only exhibited slight inhibitory effect during 
complex II and IV substrate oxidation. Taken together, these findings confirmed that 
meloxicam is a true uncoupler which stimulated state-4 but depressed state-3 
respiration, diminished MMP and decreased the rate of ATP biosynthesis in isolated 
rat kidney mitochondria. In contrast, diclofenac seemed to be respiratory inhibitor of 
NAD-linked substrates in addition to its role as an uncoupler.  
 
4.1.2 Inhibition of malate-aspartate shuttle by diclofenac 
Since diclofenac showed a preferential inhibition on the rate of ATP 
biosynthesis from the oxidation of glutamate/malate compared to succinate and 
TMPD/ascorbate, this differential effect of diclofenac alluded to its possible action on 
the activities of dehydrogenases related to the metabolism of glutamate and malate. 
However, NADH dehydrogenase, glutamate dehydrogenase and malate 
dehydrogenase were found to be unaffected when their activities were measured in the 
presence of diclofenac.  
 
Uncouplers, being able to dissipate the electrochemical gradient across the inner 
mitochondrial membrane, have been reported to affect some electrogenic carriers of 
the metabolite-transporting systems in mitochondria (LaNoue and Schoolwerth, 1979). 
There are two main transport pathways for the transport of cytosolic reducing 
equivalents into the matrix, namely the α-glycerophosphate and malate-aspartate 
shuttles. However, it appears that in kidney and liver, the malate-aspartate shuttle is 
more important and hence the effect of diclofenac on malate-aspartate shuttle was 
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examined. Under normal physiological condition, this shuttle system is crucial 
because NADH does not penetrate the mitochondrial membrane. Therefore, indirect 
routes must exist for transporting the reducing equivalents formed in the cytosol by 
glycolysis into the mitochondria. Electrons can be transported into mitochondria as 
malate via the oxoglutarate/malate carrier that exchanges α-ketoglutarate for malate. 
The reducing equivalent is then passed to NAD in the matrix by the action of malate 
dehydrogenase (MDH). The product of this reaction (oxaloacetate) is transaminated to 
aspartate by glutamate-oxaloacetate transaminase. The aspartate is then transported 
out of the mitochondria in exchange for glutamate via the aspartate/glutamate carrier. 
The cytosolic aspartate is converted to oxaloacetate and then to malate to complete 






Fig. 21. Schematic of malate-aspartate shuttle. AGC, aspartate/glutamate carrier; 
cAST and mAST, cytosolic and mitochondrial aspartate aminotransferase; cMDH and 






Due to the electrogenic nature of the aspartate/glutamate carrier, the findings on 
a compromise in MMP by diclofenac suggested that this transporter might be 
involved. Results obtained from the measurement of the malate-aspartate shuttle 
capacity demonstrated that this was indeed the case. The malate-aspartate shuttle 
activity was inhibited by diclofenac in a dose-dependent manner. In addition, a 
mixed-type of inhibition was concluded from the Lineweaver-Burk plot. By inhibiting 
the entry of glutamate/malate, diclofenac would limit the substrates bioavailability 
and thus resulted in a greater inhibitory effect on the rate of ATP biosynthesis when 
these substrates were used. The limitation of the glutamate/malate bioavailability by 
diclofenac was further proven by the results which showed that the production of 
intra-mitochondrial NAD(P)H from glutamate/malate was indeed decreased. This 
explained why the inhibitory effect of diclofenac on the rate of ATP biosynthesis was 
more pronounced under glutamate/malate oxidation compared to succinate oxidation. 
The entry of succinate depends on another transport carrier which is non-electrogenic 
and therefore its bioavailability is unlikely to be compromised (LaNoue and 
Schoolwerth, 1979). Both glutamate and malate were reported in kidney at 10 to 100 
times higher in concentrations compared to their corresponding keto acids 
(Williamson and Brosnan, 1975) alluding to their importance as endogenous 
respiratory substrates. In view of this, it was hypothesized that diclofenac might exert 
a very detrimental effect on kidney as this organ is highly dependent on ATP due to 
the need for supporting ATP-dependent processes such as the active sodium 





4.2 Studies in cultured kidney cells – MDCK II and LLC-PK1 
In addition to the studies at organelle level using isolated kidney mitochondria, 
the effects of diclofenac and meloxicam were also studied at cellular level using 
established kidney cell lines – MDCK II and LLC-PK1, which represent the distal 
tubule/collecting duct and proximal tubule, respectively. The aim is to investigate the 
cytotoxicity of diclofenac and meloxicam, and to further clarify the mechanism(s) of 
cell death induced by them. These two cell lines were chosen as they can be grown 
continuously and are well characterized for the use in nephrotoxicity studies (Wilson, 
1986). A ten times higher concentration of the drugs (500µM) was used in the 
experiments on intact cells compared to the experiments on mitochondria as this is the 
concentration that causes significant cytotoxicity within the time points being studied. 
This might be due to factors such as cellular membrane barrier, drug diffusion, active 
transport into different cell organelles, or the buffering capacity of the cytoplasm, 
thereby prevent the accumulation of active drug in or near mitochondria to cause 
mitochondrial dysfunction (Krause et al., 2003).  
 
It is known that cell death can follow two distinct pathways, apoptosis or 
necrosis (Fig. 22). Necrosis appears to be the result of acute cellular dysfunction in 
response to severe stress conditions or after exposure to toxic agents, and is a 
relatively passive process associated with rapid cellular ATP depletion. On the other 
hand, apoptosis is a form of cell death that occurs during several pathological 
situations in multicellular organisms and constitutes a common mechanism of cell 
replacement, tissue remodeling, and removal of damaged cells. The distinction 
between apoptosis and necrosis goes beyond theoretical considerations: while 
apoptotic cells are readily engulfed by vicinal phagocytes, necrosis ends in cell 
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membrane disintegration and dissemination of intracellular material, with severe 
damage for the surrounding tissue. Therefore, the investigation of whether a drug 
causes apoptosis or necrosis is of great significance, especially when the same applies 
in vivo. In this regard, the mode of cell death induced by diclofenac and meloxicam 
was focused in the present study. Etoposide, which is a topoisomerase II inhibitor 
known to induce DNA breaks and hence causes apoptosis (Karpinich et al., 2002), 
was included as a positive control for comparison.   
 
Fig. 22. Two different modes of cell death. The remains of the apoptotic cells are 
engulfed by neighboring cells while the rupture of the plasma membrane of necrotic 
cells is associated with inflammation. (diagram taken and modified from 







4.2.1 Diclofenac was more toxic than meloxicam and LLC-PK1 cells were 
more sensitive to drug toxicity than MDCK II cells 
From the results obtained from cell viability assay, it was evident that 
meloxicam was less toxic than diclofenac in cultured renal cells. This finding supports 
the in vivo studies carried out by Swan et al. (2006) which reported that meloxicam is 
of low toxicity to a wide range of avian species compared to diclofenac as proven by 
the absence of kidney damage after meloxicam administration to the birds. In the 
present study, diclofenac was able to cause cell death at lower drug concentration as 
well as at shorter time course in comparison to meloxicam. This phenomenon was 
seen in both MDCK II and LLC-PK1 cell lines. Interestingly, results showed that 
LLC-PK1 cells have a higher sensitivity towards drug toxicity than MDCK II cells, 
suggesting that epithelial cells from proximal tubule origin are more prone to drug-
mediated cell death. This could be explained by the fact that the proximal tubule is the 
most common site of toxicant-induced renal injury while chemically-induced injury to 
the more distal tubular structures is an infrequent occurrence (Schnellmann, 2001). 
The reasons for this relate in part to the selective accumulation of xenobiotics into 
proximal tubule. The distal tubule is characterized by a relatively tight epithelium 
with high electrical resistance while the proximal tubule has a leaky epithelium, thus 
favoring the flux of compounds into proximal tubular cells (Schnellmann, 2001). 
Besides the leakiness, the proximal tubule contains numerous transport systems 
capable of driving concentrative transport of many metabolic substrates. As such, if 
xenobiotics were to be present in the blood stream, there is a high possibility of 
concentrating the xenobiotics in the proximal tubular cells, thus results in proximal 
tubular injury. Even though the higher susceptibility of LLC-PK1 cells towards both 
meloxicam and diclofenac could be due to the greater uptake of the drugs into the 
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cells, the intrinsic sensitivity of the LLC-PK1 cell line towards any xenobiotic might 
also play a role.  
 
4.2.2  Different mode of cell death induced by meloxicam and diclofenac in   
MDCK II cells 
4.2.2.1 Cellular morphological changes of MDCK II cells 
Etoposide-treated cells were used as a reference for the indication of apoptotic 
cell death. The most remarkable changes after the cells were challenged with 
etoposide included detachment of the cellular monolayer, rounded up of the cells and 
increase in the number of apoptotic bodies that were floating in the media with 
increasing exposure time. Meloxicam-treated cells were found to display similar 
morphological changes as those observed for etoposide-treated cells, thus suggesting 
that meloxicam induced cell death in MDCK II cells via apoptosis. On the other hand, 
it was found that the diclofenac-treated cells seemed to have less apoptotic bodies but 
the loss of normal cellular morphology was evident. It had been reported by Rello et 
al. (2005) that apoptotic cell death could be characterized by cell rounding and 
detachment due to the loss of cellular adhesion to the substrate while necrotic cell 
death could be characterized by flattening and occurrence of attached cell remnants. 
In view of this, it is suggested that the diclofenac-treated cells might have undergone 







4.2.2.2 Caspase activation and the release of cytochrome c 
Caspases, a family of cysteine proteases, are well-known molecular executioners 
of apoptosis as they bring about most of the morphological and biochemical 
characteristics of apoptotic cell death. Three major pathways have been elucidated so 
far for caspase-dependent apoptosis, which are the extrinsic death-receptor-mediated 
pathway, the intrinsic mitochondrial pathway and the granzyme B pathway. All these 
three pathways result in activating caspase-3. With regard to the intrinsic 
mitochondrial pathway, the release of cytochrome c from the mitochondrial 
intermembrane space into the cytosol represents a central coordinating step (Liu et al., 
1996). Cytoplasmic cytochrome c is able to induce a caspase-3 activating complex, 
composed of cytochrome c, Apaf-1, dATP and procaspase-9, known as apoptosome. 
In the current study, experiments were carried out to examine the activity of caspases 
as well as the release of cytochrome c. 
 
Caspase-3 activity was found to be increased by etoposide treatment time-
dependently from 3 to 12 h of drug exposure period. At 24 h time point, caspase-3 
activity was minimal as most of the apoptotic cells might have already undergone 
secondary necrosis. In vivo, apoptotic bodies are phagocytosed rapidly by 
macrophages and neighboring epithelial cells, with subsequent lysosomal degradation. 
In vitro, however, apoptotic bodies which remain suspended in culture media undergo 
degenerative changes, such as organelle disruption and membrane rupture, and this 
terminal process of cell death is referred to as secondary necrosis (Allen et al., 1997; 
Padanilam, 2003).  It should be noted that the caspase activity was increased with the 
increase in the number of rounded and detached cells, suggesting that the 
morphologic alterations being observed were due to apoptosis. Meloxicam-treated 
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cells displayed a similar trend of caspase activation as those with etoposide, although 
the degree of activation was lower. For diclofenac-treated cells, the caspase-3 activity 
did not increase significantly from 6 to 12 h time point, which correlated with the 
morphologic alterations as there was no increase in the cells with apoptotic 
morphology. This lack of significant increase in caspase-3 activity suggested that the 
diclofenac-induced cell death could have switched from apoptosis to necrosis after 
prolonged period of drug exposure. This phenomenon is not uncommon as there is a 
general rule that apoptosis is replaced by necrosis when the strength of a damaging 
factor reaches a certain threshold (Skulachev, 2006; Nicotera et al., 1998). Since 
caspase-3 is a downstream caspase which can be activated either by caspase-8 via 
death-receptor-mediated pathway or caspase-9 via intrinsic mitochondrial pathway, 
the activities of caspase-8 and -9 were also determined. It was found that caspase-9 
activation was parallel with caspase-3 activation while the caspase-8 activation was 
minimal. This showed that the etoposide-, meloxicam- and diclofenac-induced cell 
death was more likely to involve the intrinsic mitochondrial pathway rather than the 
death-receptor mediated pathway.  
 
Coincidently, immunoblot assay using cytosolic extracts revealed the presence 
of cytochrome c in drug-treated cells. The purity of the cytosolic fractions preparation 
was proven by the absence of mitochondrial contaminants such as VDAC protein. It 
was evident that the cytosolic cytochrome c was increased in a time-dependent 
manner (0 - 12 h) in etoposide- and meloxicam-treated cells but not in diclofenac-
treated cells. In addition, the amount of released cytochrome c was also lower after 
diclofenac treatment compared to etoposide and meloxicam treatment. Taken together, 
these data suggested that etoposide and meloxicam induced caspase-dependent 
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apoptosis exclusively executed along the intrinsic (caspase-9-dependent) pathway 
without apparent participation of the extrinsic (caspase-8-dependent) pathway; 
whereas the cell death caused by diclofenac may be viewed as a consequence of 
aborted apoptosis which ended up with necrosis due to the failure of the apoptotic 





Fig. 23. Diagram showing the effects of meloxicam and diclofenac on MDCK II 
cells in terms of the release of cytochrome c and caspase activation. Dotted arrow 













4.2.2.3 Elevation of intracellular ATP supporting apoptosis 
It is well recognized that cell death by apoptosis is determined by the level of 
intracellular ATP which supports a number of ATP-requiring steps including the 
activation of caspase and the formation of the apoptosome (Liu et al., 1996; 
Zamaraeva et al., 2005; Skulachev, 2006; Leist and Jaattela, 2001). The intracellular 
ATP level appeared to be a critical factor for the selection between apoptosis and 
necrosis in many cell systems (Zamaraeva et al., 2005; Skulachev, 2006; Eguchi et al., 
1997; Izyumov et al., 2004; Leist et al., 1998; Nicotera et al., 1998). This study 
showed that there was an early drug-induced elevation of intracellular ATP in MDCK 
II cells which was maintained for about 3 hours, followed by ATP depletion. This 
finding concurred with the reports by Zamaraeva et al (2005) and Atlante et al. (2005) 
which showed that the cytosolic ATP within cells undergoing apoptosis was 
maintained at a level higher than untreated control cells. This observation seemed to 
support that apoptosis was initiated after MDCK II cells were exposed to meloxicam 
and diclofenac. Studies on isolated kidney mitochondria showed that the 
mitochondrial function was compromised by diclofenac and meloxicam due to the 
uncoupling of oxidative phosphorylation resulting in the decrease of ATP 
biosynthesis. Since diclofenac and meloxicam were able to compromise 
mitochondrial functions via the inhibition of ATP synthesis, it was surprising to find 
out that the cellular ATP of drug-treated cells was higher compared to untreated cells 
during early apoptosis. This could possibly be explained by the contribution of 
glycolysis to the elevation of cytosolic ATP which had been previously proposed 
(Zamaraeva et al., 2005; Atlante et al., 2005). In the study carried out by Zamaraeva 
et al. (2005), they showed that the apoptosis-induced rise in cytosolic ATP was not 
abolished when oxidative phosphorylation was blocked by oligomycin; the rise in 
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ATP was however blocked when the glycolytic reaction was inhibited by 2-deoxy-D-
glucose. Atlante et al. (2005) also demonstrated that in the presence of oligomycin 
ATP is synthesized via glycolysis as shown by L-lactate production, and the ATP is 
rapidly used in the processes necessary for apoptosis to occur. It was thus concluded 
that the role of oxidative phosphorylation is facultative in the course of apoptosis as 
glycolysis can provide the ATP required.  
 
4.2.2.4 Externalization of PS and loss of membrane integrity 
One of the key features of apoptotic biochemistry is the changes in the plasma 
membrane. In live cells, plasma membrane phospholipids are asymmetrically 
distributed between inner and outer surfaces of the plasma membrane. It has been 
shown that loss of phospholipid asymmetry leading to exposure of phosphatidylserine 
(PS) on the outside of the plasma membrane is an early event of apoptosis (Allen et 
al., 1997; Darzynkiewicz et al., 1997; Schutte et al., 1998; Vermes et al., 1995). In 
vivo, this translocation of PS to the outer leaflet of the plasma membrane was shown 
to mediate phagocytic recognition by macrophages and subsequent removal of the 
apoptotic cells. Annexin V was initially discovered as a vascular protein with strong 
anticoagulant properties. The annexins have the biological property of binding to 
phospholipids in a Ca2+- dependent way. Annexin V binds preferentially to 
phospholipid species such as PS and shows minimal binding to phospholipids species 
such as phosphatidylcholine and sphingomyeline. By conjugating fluorescein to 
annexin V, it is possible to use such a marker to identify apoptotic cells by flow 
cytometry. However, since PS exposure also takes place during necrosis, the annexin 
V binding assay should be combined with a non-vital dye exclusion test (propidium 
iodide, PI) in order to discriminate between apoptosis and necrosis (Vermes et al., 
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1995). PI intercalates into double-stranded nuclei acids and it can penetrate cell 
membranes of dying or dead cells. During apoptosis the cells become reactive with 
annexin V but prior to the loss of the plasma membrane’s ability to exclude PI. 
Therefore, by staining cells with a combination of fluoresceinated annexin V (annexin 
V-FITC) and PI, it is possible to detect non-apoptotic live cells (FITC-/PI-), early 
apoptotic cells (FITC+/PI-) and late apoptotic/necrotic cells (FITC+/ PI+) by flow 




Fig. 24. Use of annexin V-FITC and PI for the identification of live, apoptotic, 




Cells treated with etoposide showed an increase in the apoptotic cell population 
at 12 and 18 h. There was an increase in the necrotic cell population as well, 
suggesting that some of the apoptotic cells had undergone secondary necrosis. For 
meloxicam-treated cells, the distribution of different cell populations showed 
similarity to those observed in etoposide-treated cells, with a dramatic increase in the 
apoptotic cell population which eventually contributed to the necrotic cell population 
due to secondary necrosis. On the other hand, diclofenac-induced apoptosis was less 
with a more drastic increase in the necrotic cell population at the later stage of cell 
PI 
  Plasma membrane 
  Phosphatidylserine 
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death. Due to the existence of the possibility that the double-stained cells might be 
represented by the late apoptotic cells, the prevalence of necrosis in diclofenac-treated 
cells has to be confirmed with the results obtained from other assays. From the 
changes of cellular morphology of the diclofenac-treated cells, it was observed that 
the formation of apoptotic bodies was always less than the cells treated with either 
etoposide or meloxicam. The caspase assay results were then found to correlate with 
this observation such that the caspase activity was not much elevated by diclofenac 
treatment. Taken together, these results suggested that while meloxicam elicited the 
classical apoptotic cell death pathway similar to that of etoposide treatment in MDCK 
II cells, diclofenac treatment caused a switch from apoptosis to necrosis during the 
extended period of exposure to a relatively high dose of drug. 
 
4.2.3  Meloxicam and diclofenac caused a caspase-independent necrosis in 
LLC-PK1 cells 
4.2.3.1 Cellular morphological changes of LLC-PK1 cells 
Morphological changes in LLC-PK1 cells were observed after 3 h of incubation 
with etoposide, meloxicam and diclofenac. The changes were totally different from 
those seen in MDCK II cells, which showed black particulates between cells and on 
cell surfaces and the cell boundaries became less distinct. These black particles 
appeared to represent discharged cellular contents giving the cells a “contaminated” 
appearance. Later most of the dead cells were seen to be clumped together and they 
floated in the media. From the morphological changes observed, it seemed to be 
unlikely that the cells were dying via apoptosis. Features of apoptotic cells such as 
cell rounding and detachment from the flask and the formation of apoptotic bodies 
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were absent. Hence, the caspase-3 activity of the drug-treated cells was examined to 
investigate the involvement of apoptosis in these cells. 
 
4.2.3.2 Lack of caspase activation and elevation of cytosolic ATP in 
spite of presence of cytosolic cytochrome c 
Cellular ATP in LLC-PK1 cells remained unchanged with minimal activation of 
caspase-3 activity in drug-treated LLC-PK1 cells. This lack of caspase activation 
concurred with the morphological alterations being observed, thus suggesting that 
apoptosis might not be the mechanism of cell death for these drug-treated LLC-PK1 
cells, at least not via the classical apoptotic pathway. Despite the low caspase-3 
activity, cytochrome c was found to be released from 3 to 6 h post-drug exposure in 
meloxicam-treated cells. This indicates that apoptosis might be initiated but it 
involves a caspase-independent pathway (Shih et al., 2003). Such a caspase-
independent mode of cell death has been reported to occur in many cell types 
including primary renal proximal tubular cells (Cummings et al., 2004; Ishido et al., 
1999). In the absence of caspase activity, a number of cell events associated with 
apoptosis can still occur including PS externalization (Leist and Jaattela, 2001); this 
was also observed in the current study which will be discussed in a later section. Fig. 
25 summarizes the effects of meloxicam and diclofenac on cytochrome c release and 
caspase activation in LLC-PK1 cells.  
Despite the fact that most events in apoptosis appear to require a caspase-
mediated proteolytic step, there is evidence that apoptosis-like cell death can occur 
without the activation of effector caspases (Leist and Jäättelä, 2001). According to 
Leist and Jäättelä (2001), there are four patterns of death: apoptosis, apoptosis-like 
programmed cell death, necrosis-like programmed cell death and accidental necrosis. 
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Most published forms of caspase-independent apoptosis belongs to the apoptosis-like 
programmed cell death. In this kind of cell death, many non-caspase proteases can 
cleave at least some of the classic caspase substrates, but further study is needed to 
define the role of the individual proteases in the complex process of programmed cell 
death. Besides cytochrome c (Liu et al., 1996), another mitochondrial protein, the 
apoptosis-inducing factor (AIF) also plays a key role in apoptosis, particularly in 
caspase-independent apoptosis (Susin et al., 1999; Zamzami and Kroemer, 1999; Shih 
et al., 2003). In the study on cadmium-induced apoptosis by Shih et al. (2003), it was 
shown that cadmium conducts a caspase-independent pathway through the collapse of 
the membrane potential of mitochondria and subsequent translocation of AIF into 
nucleus. AIF causes partial chromatin condensation with high molecular weight DNA 
fragmentation that differs from those by caspase-activated-DNase (CAD) (Zamzami 
and Kroemer, 1999). Whether this AIF contributes to the caspase-independent cell 




Fig. 25. Diagram showing the effects of meloxicam and diclofenac on LLC-PK1 
cells in terms of the release of cytochrome c and caspase activation. Dotted arrows 
represent unidentified mechanisms involved in the meloxicam- and diclofenac-
induced cell death.  
 
 
4.2.3.3  Detection of early apoptosis by annexin V which eventually 
switched to necrosis 
Using the annexin V-FITC and PI double staining, it was shown that there was 
early apoptosis in diclofenac- and meloxicam-exposed LLC-PK1 cells, which was 
followed by necrosis as revealed by the strong PI staining. The early binding (3 h time 
point) of the drug-treated cells with annexin V without the loss of plasma membrane 
integrity suggested that apoptosis was initiated as an early response towards the 














of the release of cytochrome c. Therefore, the early detection of apoptosis with the 
lack of caspase activation implied that the diclofenac- and meloxicam-induced cell 
death in LLC-PK1 cells was due to a caspase-independent pathway, rather than the 
classical apoptosis which was observed in the meloxicam-treated MDCK II cells. It is 
worth noting that in both cell lines, diclofenac treatment always resulted in more 
necrotic cells compared to meloxicam treatment. The flow-cytometric data thus 
corroborated the cell viability test that diclofenac is more toxic than meloxicam. The 
effects of diclofenac and meloxicam on MDCK II and LLC-PK1 cells are summarized 


















Table 3. Comparison of the effects of meloxicam and diclofenac on MDCK II and 

















+++ + - - 
Cell detachment  
 
+++ + + + 
Formation of apoptotic bodies 
 
+++ + - - 
Necrotic cell remnants remain 
attached to the culture flask 
 
- +++ - - 
Cellular discharge into media 
 
 




Increase in intracellular ATP 
 
++ ++ - - 
Caspase-9/caspase-3 activity 
 
+++ ++ + + 
Cytochrome c release 
 
+++ ++ +++ + 
Externalization of PS 
 
+++ ++ ++ +++ 
Loss of membrane integrity 
 
++ +++ ++ +++ 
A scale of + to +++ is used with the latter showing highest increase compared to 
control;  









From the findings obtained from the experiments using isolated kidney 
mitochondria and whole cells, it can be concluded that both diclofenac and 
meloxicam are toxic to renal cells possibly by disrupting the mitochondrial function. 
Both drugs were shown to act as uncouplers by dissipating the mitochondrial 
membrane potential and hence resulted in the compromise in ATP biosynthesis. 
Diclofenac was found to be more toxic due to its capability in inhibiting the malate-
aspartate shuttle and therefore limits the bioavailability of the two main substrates – 
glutamate and malate. By compromising the mitochondrial function, it is not 
surprising that diclofenac and meloxicam could induce nephrotoxic cell death. 
However, the interesting finding is that diclofenac is indeed more toxic than 
meloxicam and the mode of cell death varied between different drugs and cell lines. 
Meloxicam caused the formation of apoptotic bodies, elevation of intracellular ATP 
supporting caspase-9/caspase-3 activation, release of cytochrome c and PS 
externalization in MDCK II cells which are characteristic features of the classical 
intrinsic mitochondrial apoptotic pathway (Padanilam, 2003). The apparent lack of 
caspase-8 activity precluded the involvement of the extrinsic death-receptor mediated 
pathway (Padanilam, 2003). Diclofenac-induced cell death in MDCK II cells however 
showed a switch from apoptosis to necrosis after a prolonged period of drug exposure. 
The caspase-independent apoptosis in LLC-PK1 cells also resulted in eventual 
necrosis-like cell death with diclofenac-treated cells being more severely damaged 
than meloxicam-treated cells. These findings supported the preference of meloxicam 
over diclofenac for veterinary use in life stock as proposed by Swan et al. (2006). The 
more damaging cell death pathway by diclofenac in both proximal and distal kidney 
tubular cells could be the cause of acute renal failure reported in man and other 
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animals (Kulling et al., 1999; Rubio-Garcia and Tellez-Molina, 1992; Cicuttini et al., 
1989; Schwartz et al., 1988; Schwaiger et al., 2004; Taib et al., 2004). Diclofenac is 
normally prescribed to elderly patients for age-related conditions of osteoarthritis, 
rheumatoid arthritis and muscle aches and pains. These patients are known to have 
compromised mitochondrial functions and are more likely to be susceptible to the 
nephrotoxicity of diclofenac. Therefore, precautions should be taken before the drug 
is prescribed to patients to reduce the risk of kidney-related deaths. In the attempt to 
reduce the incidence of NSAID-related kidney failures, future investigations should 
be carried out to verify if meloxicam is comparatively a safer drug. Experiments 
involving the use of human kidney cells are worth trying. In addition to in vitro 
studies, in vivo studies using several different animal species are also crucial due to 
the fact that the expression of COX-2 in the kidney varies between different species 
and therefore any study based on only one animal model is insufficient for the 
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